HAEMODIALYSIS: THE TOOL TO CURB MORTALITY IN COVID AKI PATIENTS WITH ELEVATED INFLAMMATORY MARKERS

Abstract

Background: In patients with multiple organ involvement and need of critical care, the severity of COVID 19 can be assessed using various biomarker of a hyperinammatory immune response. Our research aims to correlate these biomarkers with COVID severity and to comprehend the value of hemodialysis, not only in terms of lowering renal load but also in terms of enhancing outcomes by addressing the inammatory response Objective: To study the impact of haemodialysis on COVID positive patients with AKI and elevated inammatory markers (NLR, D-Dimer, Serum LDH, Serum Procalcitonin) Out of total 126 patients, 79 were survivors and 47 Results: non-survivors. In non-survivors, majority were older (p=0.009). Both the group had higher percentage of males 78.72% and 55.69% in survivors and non-survivors respectively. Mean NLR and D-dimer, procalcitonin, LDH, and prothrombin time was signicantly higher in non-survivor as compared to survivors (p<0.001). Mean serum urea and creatinine was signicantly greater in non-survivors (p<0.001). Mean number of haemodialysis sessions received by survivors were higher. Strong positive correlation was observed between CTSI versus serum procalcitonin, serum LDH, D-dimer, and NLR. Our Conclusion: study establishes NLR, D-dimer,serum procalcitonin, serum LDH to be strongly associated with both COVID CT severity and mortality making them early prognostic markers in COVID patients. It also proves the role of haemodialysis as a life-saving tool to reduce inammation while also improving kidney outcomes